Literature DB >> 32899017

The effect of Tai Chi practice on immunological function in cancer survivors: A protocol for systematic review.

Xuejiao Wang1, Lei Xu1,2, Ning Dai1, Xingzhe Yang1, Qingyun He1, Libo Tan1, Ruochong Wang1,2, Feng Li1.   

Abstract

BACKGROUND: Tai Chi has been reported to be potentially effective for health and well-being of cancer survivors. It is worth to assess the effectiveness and safety of Tai Chi on immunological function in people with cancer.
METHODS: All relevant randomized controlled trials (RCT) will be reviewed on Tai Chi for immunological function in cancer survivors. Literature searching will be conducted until March 9, 2019 from major English and Chinese databases: Cochrane Library, Excerpta Medica Database (EMBASE), PubMed, CINAHL, Sprotdicus, American Association for Cancer Research Journals, Sino-Med database, China National Knowledge Infrastructure, Chinese Science and Technique Journals Database, and Wanfang Data Chinese database. Two authors will conduct data selection and extraction independently. Quality assessment will be conducted using the risk of bias tool recommended by the Cochrane Collaboration. We will conduct data analysis using Cochrane's RevMan software (V.5.3). Forest plots and summary of findings tables will illustrate the results from a meta-analysis if sufficient studies with the same outcomes are identified. Funnel plots will be developed to evaluate reporting bias.
RESULTS: This review will summarize the evidence on Tai Chi for immunological function in cancer survivors.
CONCLUSIONS: We hope that the results of this study will provide significant evidence to assess the value Tai Chi practice on immunological function in cancer survivors. ETHICS AND DISSEMINATION: Ethics approval is not required as this study will not involve patients. The results of this study will be submitted to a peer-reviewed journal for publication.

Entities:  

Mesh:

Year:  2020        PMID: 32899017      PMCID: PMC7478452          DOI: 10.1097/MD.0000000000021869

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Cancer is a leading cause of global mortality and is responsible for 9.6 million deaths in 2018,[ and there will be >11 million cancer deaths worldwide in 2030,[ according to the World Health Organization (WHO). In some studies, the link between the immune system and cancer has been increasingly recognized. In tumor immunity, tumor cells act as antigens, immune cells and leukocytes infiltrate the tumor tissue function through chemotaxis to form immune defense.[ However, malignant tumors can change the host immune system to form mechanisms to evade immune system surveillance as they grow, and cancer patients’ immune system responses may be compromised.[ The past decade has witnessed a revolution in cancer treatments, shifting from widely targeted tumor drugs (e.g., chemotherapy and radiotherapy) to the use of antibody-based immunotherapy to regulate the immune response against tumors.[ Although with the advances of medical technology, overall cancer death rates continue to decline globally,[ cancer survivors are still suffering from adverse effects, such as reduced immune function,[ brought about by cancer and treatments for cancer. Immune function plays an important role in the prevention, progression, treatment, recurrence, and prognosis of cancer.[ Therefore, there is a need for safe, less invasive, and effective alternatives to improve the immune system. So far, American College of Sports Medicine has hold two International Multidisciplinary Roundtable on Physical Activity and Cancer Prevention and Control aimed at putting forward high lever of recommendations for cancer survivors.[ What's more, Australia[ also put up their statement about exercise medicine in cancer management, in which the role of Tai Chi emerged. Indeed, Tai Chi, as an ancient Chinese mind-body fitness regimen, is guided to be mindful of their postures, movements, and breathing, with an intensive inwardly directed focus.[ To data, there has been some scientific or empirical evidences to support the claim that, Tai Chi can benefit immunological function in cancer survivors. For the body, Tai Chi as a form of moderate intensity aerobic exercise,[ has immunomodulatory effects that could alter multiple critical phases of immune system tumor cross-talk in both tumor initiation and progression, although this area of investigation clearly remains in its infancy. In view of mind-body intervention, Tai Chi might able to reverse the effects of acute and chronic stress and reduce the activation of sympathetic nervous system,[ focusing on aspects of immunity that are regulated by stress response mechanisms, namely inflammation and anti-viral related immune responses, etc.[ Up to now, there are nearly 20 systematic reviews about the Effect of Tai Chi practice on cancer related symptoms. The primary outcome measures of the reviews included short and long-term cancer-related fatigue, quality of life, aerobic capacity, muscular strength, and flexibility.[ Although adjusting the immune system can offer potential benefits to cancer survivors, there is no systematic review evaluating the effect of Tai Chi on immune system in cancer patients thus far. Khosravi et al[ conducted separate meta-analyses in cancer survivors to determine the effects of exercise training on pro- and anti-inflammatory markers, and immune cell proportions and function. But they just explored the cytokines which is included in >3 studies, and they combined Tai Chi and yoga together leading a mixed result; Koelwyn et al[ have made a very detailed review about the relationship between physical activity and immune surveillance, immune escape and immunogenic response to the tumor. Nevertheless, there rarely has introduction of Tai Chi. So the aim of this systematic review and meta-analysis of randomized controlled trials (RCT) is to evaluate current evidence and estimate the pooled effects of Tai Chi on the immune system, as well as adverse events.

Methods and analysis

Standards

The protocol of the meta-analysis will be developed according to the Preferred Reporting Items for Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocols (PRISMA-P) guidelines. PRISMA-P is supplied in PRISMA checklist.[

Registration

Our meta-analysis protocol has been registered at the https://inplasy.com/ with registration number: INPLASY202060042. However, we plan to make a little change in the review in adjusting databases: deleting the Allied and Complementary Medicine Database (AMED) and inserting Chinese Science and Technique Journals Database (VIP) and Wanfang Data Chinese database. What's more, we would like to add 3 outcomes: cancer related fatigue (CRF), patient satisfaction, and adverse event.

Inclusion criteria

Types of studies

RCTs assessing the effects of Tai Chi on immunological function and CRF in cancer survivors will be included. Reviews, systematic reviews, case reports, editorials, and study protocols will be excluded.

Types of participants

This review will include cancer survivors diagnosed by applicable diagnostic criteria including European Society for Medical Oncology (ESMO) 2014; The World Health Organization 2017, etc, regardless of age, sex, tumor site, tumor type, tumor stage, and type of anticancer treatment received.

Types of interventions

Studies that use any form of Tai Chi regardless of the form (e.g., 24-form, 54-form, 83-form Tai Chi) in any styles (e.g., Chen, Yang, Wu, and Sun) with a minimum frequency of once per week. The intervention could be provided in the format of a Tai Chi programme alone or as a Tai Chi programme in addition to another intervention. However, Tai chi softball, Tai chi fan exercise, and other exercises requiring the help of tools are excluded.

Type of control

Studies with no treatment, other treatment forms like usual medical care, health education, pharmacotherapy, psychological therapy, cognitive behavioral therapy, and exercises other than Tai Chi such as walking, stretching, yoga, and dancing will be eligible.

Types of outcome measures

All biomarkers related to the immune system including immune related cytokines and immune cells will be recorded including but not limited to pro-inflammatory cytokines IL-6, TNF (tumor necrosis factor)-α, C-reactive protein (CRP), anti-inflammatory cytokines IL-4, IFN (interferon)-γ, cortisol, and so on. The score of cancer related fatigue. The patient satisfaction and adverse event are to be measured.

Information sources

The following databases will be searched until March 9, 2019: Cochrane Library, Excerpta Medica Database (EMBASE), PubMed, CINAHL, Sprotdicus, American Association for Cancer Research Journals, Sino-Med database, China National Knowledge Infrastructure (CNKI), Chinese Science and Technique Journals Database (VIP), and Wanfang Data Chinese database.

Search strategies

All relevant published RCTs will be identified regardless of language or publication status. The English search terms will include “Tai Chi,” “Tai Chi Chuan,” “Tai ji,” “Tai-ji,” “Tai Ji Quan,” “taijiquan,” “neoplasms,” “cancer,” “carcino,” “tumor,” “randomized controlled trial,” “randomised controlled trial,” “controlled clinical trial,” “randomly,” “Clinical,” “trial,” “random,” “randomised,” and “randomized.” The Chinese searching terms will include Tai Chi (“Tai_ji,” “Tai_ji_yun_shou,” “Tai_ji_cao,” or “Tai_ji_chuan”), cancer (“ai,” “ai_zheng,” “ai_zhong,” or “zhong_liu”) and randomized (“sui_ji,” “dui_zhao”). Detailed search strategies are available for example in Table 1: preliminary search strategy, appendixed below the references.
Table 1

Search strategies.

Search strategies.

Data selection and extraction

Selection of studies

The search results from different databases will be imported into Endnote X8 (Thomson Research Soft, USA) and duplicate citations will be removed. Three authors (XW, QH, LX) will screen the titles and abstracts independently. Full texts of all potentially relevant studies will be retrieved. Any disagreement about the selection of studies will be resolved by discussion, and a third author (ND) will arbitrate when necessary. The selection procedure is shown in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart in Fig. 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram, appendixed below the references.
Figure 1

PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta Analysis.

PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta Analysis.

Data extraction and management

Three authors (XW, QH, and LX) will extract the data from the eligible studies independently by using a pre-designed form. Any disagreements will be resolved by discussion with a fourth author (ND). The extracted data will include the following information: publication information: authors, the country where the study was conducted, journal, title, and year of publication. study designs: multiple/single centre(s), parallel/cross-over, etc. participants: sample size, diagnostic criteria, characteristics of participants (e.g., age, sex, duration, and severity of disease), the treatments have received, etc; intervention: type and/or form of Tai Chi, details of treatment and control, duration of treatment; outcome: outcomes measures, main data of the outcomes, time point of measurement, etc.

Methodological quality assessment

Studies quality will be assessed using the risk of bias tool provided by the Cochrane Handbook for Systematic Reviews of Interventions.[ This will assess the categories of bias for each study: selection bias (random sequence generation and allocation concealment), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting), and other bias (unbalanced base line, early termination). We will not report performance bias, considering the difficulties of blinding the participants and personnel in Tai Chi intervention studies. For each item, there are 3 potential bias judgements: “low risk,” “high risk,” or “unclear risk.” Trials that meet all criteria will be judged to have low risk of bias. A high risk of bias if at least 1 domain is assessed as at high risk of bias, and trials with insufficient information to judge will be classified as unclear risk of bias. Any disagreements will be resolved by discussion, with involvement of a third author (ND) where necessary.

Dealing with missing data

In the case of missing data included in study, we will contact the corresponding authors. If not successful, we will analyze available data to perform the outcome and assess the potential impact in the discussion.

Data synthesis

Data will be summarized by using risk ratios with 95% confidence interval (CI) for dichotomous outcomes or mean difference with 95% CI for continuous outcomes. It is anticipated that different scales may be used to report the same outcomes, in which case we will use the standardized mean difference (SMD). Statistical heterogeneity will be assessed using the I2 statistic (on the bases of characteristics of the included studies and the participants, details of the intervention or control, and types of outcome measurements). If the I2 statistic is <50% and the clinical heterogeneity among trials is acceptable, data will be pooled for statistical analyses using the Cochrane’ Review Manager software (V.5.3). Fixed effects model will be used to conduct the meta-analysis when the I2 statistic is <25%, otherwise random-effects model. When there is clinical heterogeneity or statistical heterogeneity (I > 50%), subgroup analysis or descriptive analysis will be conducted.

Subgroup analysis

Where data are available, subgroup analyses will be conducted to determine if effectiveness of Tai Chi is influenced by: different phrases of treatment, such as undergoing treatment, or in the post-treatment phase. Studies including patients receiving chemotherapy or radiotherapy as the initial cancer treatment or as treatment in the presence of metastasis or cancer recurrence will be classified as “undergoing cancer treatment stage,” while those studies including patients currently have gone through chemotherapy or radiotherapy will be defined as “post-cancer treatment stage.” Also we will conduct subgroup analyses for time frame, intervention duration, cancer type, and so on if needed.

Sensitivity analysis

To ensure the robustness of evidence, we will perform sensitivity analysis to assess the impact of studies depending on study characteristics identified during the review process.

Publication bias

When sufficient RCTs are available for meta-analysis, we will conduct tests to explore publication bias using funnel plot asymmetry.

Ethics and dissemination

Ethical approval is not required because all data used in this study will be anonymous with no concerns regarding privacy. The findings will be disseminated through a peer-review publication, to inform both clinical practice and further research on Tai Chi and cancer.

Discussion

To the best of our knowledge, this is the first systematic review to identify the effect of Tai Chi practice on immunological function in cancer survivors based on major English and Chinese databases from a global perspective. This study includes a comprehensive search strategy across several health research-related databases to reduce the possibility of duplication and ensure the inclusion of representative studies. The review will follow robust guidelines and the quality of the papers included will be assessed using a validated tool. Gaps in the literature will be identified to provide suggestion for future research on Tai Chi for cancer. This review still has some limitations. We put more attention on immune measures level in cancer survivors, but less on the immunology-related clinical significance. There now exists an unprecedented opportunity for exercise-oncology researchers to unlock the potential therapeutic promise of exercise in cancer initiation and progression. But to do this require the design of research that involve multidisciplinary teams with expertise in exercise science, immunology, cancer biology, and clinical oncology.

Acknowledgments

The authors are grateful for the valuable suggestions provided by Dr Li Bo (Beijing institute of traditional Chinese medicine, Beijing Chinese Medicine Hospital Affiliated to Capital Medical University).

Author contributions

Xuejiao Wang and Lei Xu are joint first authors. Xuejiao Wang contributed to the conception of the study and wrote the draft of manuscript, and the final manuscript was revised by Lei Xu. The search strategy was developed by all of the authors. Qingyun He, Lei Xu, Xuejiao Wang, Ning Dai will search, extract data, assess the risk of bias, and complete the data synthesis. Ning Dai and Xingzhe Yang both contibuted to the methodology. Ruochong Wang and Libo Tan are responsible for project administration and supervision. Feng Li and Xuejiao Wang obtained funding and will arbitrate in case of disagreement and ensure the absence of errors. All authors have read and approved the final manuscript.
  42 in total

Review 1.  Reciprocal regulation of the neural and innate immune systems.

Authors:  Michael R Irwin; Steven W Cole
Journal:  Nat Rev Immunol       Date:  2011-08-05       Impact factor: 53.106

Review 2.  Cytotoxic T cells.

Authors:  Mads Hald Andersen; David Schrama; Per Thor Straten; Jürgen C Becker
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

Review 3.  Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis.

Authors:  Nasim Khosravi; Lee Stoner; Vahid Farajivafa; Erik D Hanson
Journal:  Brain Behav Immun       Date:  2019-08-24       Impact factor: 7.217

Review 4.  Health benefits of qigong or tai chi for cancer patients: a systematic review and meta-analyses.

Authors:  Yingchun Zeng; Taizhen Luo; Huaan Xie; Meiling Huang; Andy S K Cheng
Journal:  Complement Ther Med       Date:  2013-12-18       Impact factor: 2.446

5.  Tai Chi Chih acutely decreases sympathetic nervous system activity in older adults.

Authors:  Sarosh J Motivala; John Sollers; Julian Thayer; Michael R Irwin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-11       Impact factor: 6.053

Review 6.  The effect of Tai Chi on four chronic conditions-cancer, osteoarthritis, heart failure and chronic obstructive pulmonary disease: a systematic review and meta-analyses.

Authors:  Yi-Wen Chen; Michael A Hunt; Kristin L Campbell; Kortni Peill; W Darlene Reid
Journal:  Br J Sports Med       Date:  2015-09-17       Impact factor: 13.800

Review 7.  The immune system--is it relevant to cancer development, progression and treatment?

Authors:  R J Prestwich; F Errington; P Hatfield; A E Merrick; E J Ilett; P J Selby; A A Melcher
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-11-26       Impact factor: 4.126

Review 8.  Does Tai Chi relieve fatigue? A systematic review and meta-analysis of randomized controlled trials.

Authors:  Yu Xiang; Liming Lu; Xiankun Chen; Zehuai Wen
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

9.  Aerobic physical exercise for adult patients with haematological malignancies.

Authors:  Linus Knips; Nils Bergenthal; Fiona Streckmann; Ina Monsef; Thomas Elter; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2019-01-31

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Degu Abate; Naghmeh Abbasi; Hedayat Abbastabar; Foad Abd-Allah; Omar Abdel-Rahman; Ahmed Abdelalim; Amir Abdoli; Ibrahim Abdollahpour; Abdishakur S M Abdulle; Nebiyu Dereje Abebe; Haftom Niguse Abraha; Laith Jamal Abu-Raddad; Ahmed Abualhasan; Isaac Akinkunmi Adedeji; Shailesh M Advani; Mohsen Afarideh; Mahdi Afshari; Mohammad Aghaali; Dominic Agius; Sutapa Agrawal; Ayat Ahmadi; Elham Ahmadian; Ehsan Ahmadpour; Muktar Beshir Ahmed; Mohammad Esmaeil Akbari; Tomi Akinyemiju; Ziyad Al-Aly; Assim M AlAbdulKader; Fares Alahdab; Tahiya Alam; Genet Melak Alamene; Birhan Tamene T Alemnew; Kefyalew Addis Alene; Cyrus Alinia; Vahid Alipour; Syed Mohamed Aljunid; Fatemeh Allah Bakeshei; Majid Abdulrahman Hamad Almadi; Amir Almasi-Hashiani; Ubai Alsharif; Shirina Alsowaidi; Nelson Alvis-Guzman; Erfan Amini; Saeed Amini; Yaw Ampem Amoako; Zohreh Anbari; Nahla Hamed Anber; Catalina Liliana Andrei; Mina Anjomshoa; Fereshteh Ansari; Ansariadi Ansariadi; Seth Christopher Yaw Appiah; Morteza Arab-Zozani; Jalal Arabloo; Zohreh Arefi; Olatunde Aremu; Habtamu Abera Areri; Al Artaman; Hamid Asayesh; Ephrem Tsegay Asfaw; Alebachew Fasil Ashagre; Reza Assadi; Bahar Ataeinia; Hagos Tasew Atalay; Zerihun Ataro; Suleman Atique; Marcel Ausloos; Leticia Avila-Burgos; Euripide F G A Avokpaho; Ashish Awasthi; Nefsu Awoke; Beatriz Paulina Ayala Quintanilla; Martin Amogre Ayanore; Henok Tadesse Ayele; Ebrahim Babaee; Umar Bacha; Alaa Badawi; Mojtaba Bagherzadeh; Eleni Bagli; Senthilkumar Balakrishnan; Abbas Balouchi; Till Winfried Bärnighausen; Robert J Battista; Masoud Behzadifar; Meysam Behzadifar; Bayu Begashaw Bekele; Yared Belete Belay; Yaschilal Muche Belayneh; Kathleen Kim Sachiko Berfield; Adugnaw Berhane; Eduardo Bernabe; Mircea Beuran; Nickhill Bhakta; Krittika Bhattacharyya; Belete Biadgo; Ali Bijani; Muhammad Shahdaat Bin Sayeed; Charles Birungi; Catherine Bisignano; Helen Bitew; Tone Bjørge; Archie Bleyer; Kassawmar Angaw Bogale; Hunduma Amensisa Bojia; Antonio M Borzì; Cristina Bosetti; Ibrahim R Bou-Orm; Hermann Brenner; Jerry D Brewer; Andrey Nikolaevich Briko; Nikolay Ivanovich Briko; Maria Teresa Bustamante-Teixeira; Zahid A Butt; Giulia Carreras; Juan J Carrero; Félix Carvalho; Clara Castro; Franz Castro; Ferrán Catalá-López; Ester Cerin; Yazan Chaiah; Wagaye Fentahun Chanie; Vijay Kumar Chattu; Pankaj Chaturvedi; Neelima Singh Chauhan; Mohammad Chehrazi; Peggy Pei-Chia Chiang; Tesfaye Yitna Chichiabellu; Onyema Greg Chido-Amajuoyi; Odgerel Chimed-Ochir; Jee-Young J Choi; Devasahayam J Christopher; Dinh-Toi Chu; Maria-Magdalena Constantin; Vera M Costa; Emanuele Crocetti; Christopher Stephen Crowe; Maria Paula Curado; Saad M A Dahlawi; Giovanni Damiani; Amira Hamed Darwish; Ahmad Daryani; José das Neves; Feleke Mekonnen Demeke; Asmamaw Bizuneh Demis; Birhanu Wondimeneh Demissie; Gebre Teklemariam Demoz; Edgar Denova-Gutiérrez; Afshin Derakhshani; Kalkidan Solomon Deribe; Rupak Desai; Beruk Berhanu Desalegn; Melaku Desta; Subhojit Dey; Samath Dhamminda Dharmaratne; Meghnath Dhimal; Daniel Diaz; Mesfin Tadese Tadese Dinberu; Shirin Djalalinia; David Teye Doku; Thomas M Drake; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Hedyeh Ebrahimi; Andem Effiong; Aziz Eftekhari; Iman El Sayed; Maysaa El Sayed Zaki; Shaimaa I El-Jaafary; Ziad El-Khatib; Demelash Abewa Elemineh; Hajer Elkout; Richard G Ellenbogen; Aisha Elsharkawy; Mohammad Hassan Emamian; Daniel Adane Endalew; Aman Yesuf Endries; Babak Eshrati; Ibtihal Fadhil; Vahid Fallah Omrani; Mahbobeh Faramarzi; Mahdieh Abbasalizad Farhangi; Andrea Farioli; Farshad Farzadfar; Netsanet Fentahun; Eduarda Fernandes; Garumma Tolu Feyissa; Irina Filip; Florian Fischer; James L Fisher; Lisa M Force; Masoud Foroutan; Marisa Freitas; Takeshi Fukumoto; Neal D Futran; Silvano Gallus; Fortune Gbetoho Gankpe; Reta Tsegaye Gayesa; Tsegaye Tewelde Gebrehiwot; Gebreamlak Gebremedhn Gebremeskel; Getnet Azeze Gedefaw; Belayneh K Gelaw; Birhanu Geta; Sefonias Getachew; Kebede Embaye Gezae; Mansour Ghafourifard; Alireza Ghajar; Ahmad Ghashghaee; Asadollah Gholamian; Paramjit Singh Gill; Themba T G Ginindza; Alem Girmay; Muluken Gizaw; Ricardo Santiago Gomez; Sameer Vali Gopalani; Giuseppe Gorini; Bárbara Niegia Garcia Goulart; Ayman Grada; Maximiliano Ribeiro Guerra; Andre Luiz Sena Guimaraes; Prakash C Gupta; Rahul Gupta; Kishor Hadkhale; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Randah R Hamadeh; Samer Hamidi; Lolemo Kelbiso Hanfore; Josep Maria Haro; Milad Hasankhani; Amir Hasanzadeh; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Andualem Henok; Nathaniel J Henry; Claudiu Herteliu; Hagos D Hidru; Chi Linh Hoang; Michael K Hole; Praveen Hoogar; Nobuyuki Horita; H Dean Hosgood; Mostafa Hosseini; Mehdi Hosseinzadeh; Mihaela Hostiuc; Sorin Hostiuc; Mowafa Househ; Mohammedaman Mama Hussen; Bogdan Ileanu; Milena D Ilic; Kaire Innos; Seyed Sina Naghibi Irvani; Kufre Robert Iseh; Sheikh Mohammed Shariful Islam; Farhad Islami; Nader Jafari Balalami; Morteza Jafarinia; Leila Jahangiry; Mohammad Ali Jahani; Nader Jahanmehr; Mihajlo Jakovljevic; Spencer L James; Mehdi Javanbakht; Sudha Jayaraman; Sun Ha Jee; Ensiyeh Jenabi; Ravi Prakash Jha; Jost B Jonas; Jitendra Jonnagaddala; Tamas Joo; Suresh Banayya Jungari; Mikk Jürisson; Ali Kabir; Farin Kamangar; André Karch; Narges Karimi; Ansar Karimian; Amir Kasaeian; Gebremicheal Gebreslassie Kasahun; Belete Kassa; Tesfaye Dessale Kassa; Mesfin Wudu Kassaw; Anil Kaul; Peter Njenga Keiyoro; Abraham Getachew Kelbore; Amene Abebe Kerbo; Yousef Saleh Khader; Maryam Khalilarjmandi; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Khaled Khatab; Amir Khater; Maryam Khayamzadeh; Maryam Khazaee-Pool; Salman Khazaei; Abdullah T Khoja; Mohammad Hossein Khosravi; Jagdish Khubchandani; Neda Kianipour; Daniel Kim; Yun Jin Kim; Adnan Kisa; Sezer Kisa; Katarzyna Kissimova-Skarbek; Hamidreza Komaki; Ai Koyanagi; Kristopher J Krohn; Burcu Kucuk Bicer; Nuworza Kugbey; Vivek Kumar; Desmond Kuupiel; Carlo La Vecchia; Deepesh P Lad; Eyasu Alem Lake; Ayenew Molla Lakew; Dharmesh Kumar Lal; Faris Hasan Lami; Qing Lan; Savita Lasrado; Paolo Lauriola; Jeffrey V Lazarus; James Leigh; Cheru Tesema Leshargie; Yu Liao; Miteku Andualem Limenih; Stefan Listl; Alan D Lopez; Platon D Lopukhov; Raimundas Lunevicius; Mohammed Madadin; Sameh Magdeldin; Hassan Magdy Abd El Razek; Azeem Majeed; Afshin Maleki; Reza Malekzadeh; Ali Manafi; Navid Manafi; Wondimu Ayele Manamo; Morteza Mansourian; Mohammad Ali Mansournia; Lorenzo Giovanni Mantovani; Saman Maroufizadeh; Santi Martini S Martini; Tivani Phosa Mashamba-Thompson; Benjamin Ballard Massenburg; Motswadi Titus Maswabi; Manu Raj Mathur; Colm McAlinden; Martin McKee; Hailemariam Abiy Alemu Meheretu; Ravi Mehrotra; Varshil Mehta; Toni Meier; Yohannes A Melaku; Gebrekiros Gebremichael Meles; Hagazi Gebre Meles; Addisu Melese; Mulugeta Melku; Peter T N Memiah; Walter Mendoza; Ritesh G Menezes; Shahin Merat; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Tomasz Miazgowski; Kebadnew Mulatu M Mihretie; Ted R Miller; Edward J Mills; Seyed Mostafa Mir; Hamed Mirzaei; Hamid Reza Mirzaei; Rashmi Mishra; Babak Moazen; Dara K Mohammad; Karzan Abdulmuhsin Mohammad; Yousef Mohammad; Aso Mohammad Darwesh; Abolfazl Mohammadbeigi; Hiwa Mohammadi; Moslem Mohammadi; Mahdi Mohammadian; Abdollah Mohammadian-Hafshejani; Milad Mohammadoo-Khorasani; Reza Mohammadpourhodki; Ammas Siraj Mohammed; Jemal Abdu Mohammed; Shafiu Mohammed; Farnam Mohebi; Ali H Mokdad; Lorenzo Monasta; Yoshan Moodley; Mahmood Moosazadeh; Maryam Moossavi; Ghobad Moradi; Mohammad Moradi-Joo; Maziar Moradi-Lakeh; Farhad Moradpour; Lidia Morawska; Joana Morgado-da-Costa; Naho Morisaki; Shane Douglas Morrison; Abbas Mosapour; Seyyed Meysam Mousavi; Achenef Asmamaw Muche; Oumer Sada S Muhammed; Jonah Musa; Ashraf F Nabhan; Mehdi Naderi; Ahamarshan Jayaraman Nagarajan; Gabriele Nagel; Azin Nahvijou; Gurudatta Naik; Farid Najafi; Luigi Naldi; Hae Sung Nam; Naser Nasiri; Javad Nazari; Ionut Negoi; Subas Neupane; Polly A Newcomb; Haruna Asura Nggada; Josephine W Ngunjiri; Cuong Tat Nguyen; Leila Nikniaz; Dina Nur Anggraini Ningrum; Yirga Legesse Nirayo; Molly R Nixon; Chukwudi A Nnaji; Marzieh Nojomi; Shirin Nosratnejad; Malihe Nourollahpour Shiadeh; Mohammed Suleiman Obsa; Richard Ofori-Asenso; Felix Akpojene Ogbo; In-Hwan Oh; Andrew T Olagunju; Tinuke O Olagunju; Mojisola Morenike Oluwasanu; Abidemi E Omonisi; Obinna E Onwujekwe; Anu Mary Oommen; Eyal Oren; Doris D V Ortega-Altamirano; Erika Ota; Stanislav S Otstavnov; Mayowa Ojo Owolabi; Mahesh P A; Jagadish Rao Padubidri; Smita Pakhale; Amir H Pakpour; Adrian Pana; Eun-Kee Park; Hadi Parsian; Tahereh Pashaei; Shanti Patel; Snehal T Patil; Alyssa Pennini; David M Pereira; Cristiano Piccinelli; Julian David Pillay; Majid Pirestani; Farhad Pishgar; Maarten J Postma; Hadi Pourjafar; Farshad Pourmalek; Akram Pourshams; Swayam Prakash; Narayan Prasad; Mostafa Qorbani; Mohammad Rabiee; Navid Rabiee; Amir Radfar; Alireza Rafiei; Fakher Rahim; Mahdi Rahimi; Muhammad Aziz Rahman; Fatemeh Rajati; Saleem M Rana; Samira Raoofi; Goura Kishor Rath; David Laith Rawaf; Salman Rawaf; Robert C Reiner; Andre M N Renzaho; Nima Rezaei; Aziz Rezapour; Ana Isabel Ribeiro; Daniela Ribeiro; Luca Ronfani; Elias Merdassa Roro; Gholamreza Roshandel; Ali Rostami; Ragy Safwat Saad; Parisa Sabbagh; Siamak Sabour; Basema Saddik; Saeid Safiri; Amirhossein Sahebkar; Mohammad Reza Salahshoor; Farkhonde Salehi; Hosni Salem; Marwa Rashad Salem; Hamideh Salimzadeh; Joshua A Salomon; Abdallah M Samy; Juan Sanabria; Milena M Santric Milicevic; Benn Sartorius; Arash Sarveazad; Brijesh Sathian; Maheswar Satpathy; Miloje Savic; Monika Sawhney; Mehdi Sayyah; Ione J C Schneider; Ben Schöttker; Mario Sekerija; Sadaf G Sepanlou; Masood Sepehrimanesh; Seyedmojtaba Seyedmousavi; Faramarz Shaahmadi; Hosein Shabaninejad; Mohammad Shahbaz; Masood Ali Shaikh; Amir Shamshirian; Morteza Shamsizadeh; Heidar Sharafi; Zeinab Sharafi; Mehdi Sharif; Ali Sharifi; Hamid Sharifi; Rajesh Sharma; Aziz Sheikh; Reza Shirkoohi; Sharvari Rahul Shukla; Si Si; Soraya Siabani; Diego Augusto Santos Silva; Dayane Gabriele Alves Silveira; Ambrish Singh; Jasvinder A Singh; Solomon Sisay; Freddy Sitas; Eugène Sobngwi; Moslem Soofi; Joan B Soriano; Vasiliki Stathopoulou; Mu'awiyyah Babale Sufiyan; Rafael Tabarés-Seisdedos; Takahiro Tabuchi; Ken Takahashi; Omid Reza Tamtaji; Mohammed Rasoul Tarawneh; Segen Gebremeskel Tassew; Parvaneh Taymoori; Arash Tehrani-Banihashemi; Mohamad-Hani Temsah; Omar Temsah; Berhe Etsay Tesfay; Fisaha Haile Tesfay; Manaye Yihune Teshale; Gizachew Assefa Tessema; Subash Thapa; Kenean Getaneh Tlaye; Roman Topor-Madry; Marcos Roberto Tovani-Palone; Eugenio Traini; Bach Xuan Tran; Khanh Bao Tran; Afewerki Gebremeskel Tsadik; Irfan Ullah; Olalekan A Uthman; Marco Vacante; Maryam Vaezi; Patricia Varona Pérez; Yousef Veisani; Simone Vidale; Francesco S Violante; Vasily Vlassov; Stein Emil Vollset; Theo Vos; Kia Vosoughi; Giang Thu Vu; Isidora S Vujcic; Henry Wabinga; Tesfahun Mulatu Wachamo; Fasil Shiferaw Wagnew; Yasir Waheed; Fitsum Weldegebreal; Girmay Teklay Weldesamuel; Tissa Wijeratne; Dawit Zewdu Wondafrash; Tewodros Eshete Wonde; Adam Belay Wondmieneh; Hailemariam Mekonnen Workie; Rajaram Yadav; Abbas Yadegar; Ali Yadollahpour; Mehdi Yaseri; Vahid Yazdi-Feyzabadi; Alex Yeshaneh; Mohammed Ahmed Yimam; Ebrahim M Yimer; Engida Yisma; Naohiro Yonemoto; Mustafa Z Younis; Bahman Yousefi; Mahmoud Yousefifard; Chuanhua Yu; Erfan Zabeh; Vesna Zadnik; Telma Zahirian Moghadam; Zoubida Zaidi; Mohammad Zamani; Hamed Zandian; Alireza Zangeneh; Leila Zaki; Kazem Zendehdel; Zerihun Menlkalew Zenebe; Taye Abuhay Zewale; Arash Ziapour; Sanjay Zodpey; Christopher J L Murray
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.